Liquidia vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Liquidia Technologies Inc (LQDA)

Q3 202629 Jun – 2 Oct 2026

▲2▼2

Yutrepia Launch Booms, Then Patent Ruling Threatens Key Market

Yutrepia launch exceeds expectations Yutrepia's launch delivered strong growth: annualized revenue hit about $520 million, with $300 million in first-half sales, over 5,000 patients started, and four straight profitable quarters. Analysts raised estimates as the stock more than doubled.
This is the main positive force behind the stock's rise during the period.
Patent ruling threatens PH-ILD market A Delaware court ruled that Yutrepia infringes a United Therapeutics patent covering PH-ILD use, threatening a key market and future sales. This legal setback reversed earlier momentum and weighed heavily on the stock.
This is the major negative event that changed the stock's trajectory.
Analyst downgrades and price target cuts Wells Fargo, BTIG, and Raymond James downgraded the stock and sharply cut price targets following the patent ruling, reflecting reduced confidence in future sales and earnings.
These downgrades amplified the negative impact of the patent ruling on the stock price.
FDA Fast Track for Raynaud's The FDA granted Fast Track status for Yutrepia in scleroderma-related Raynaud's phenomenon, a smaller, early-stage opportunity that partly offsets the negative patent news.
This is a new positive development that provides some counterbalance to the negative drivers.

September 20265 Aug – 2 Oct 2026

▲2▼2

Liquidia's Yutrepia Boom Meets Patent Setback

Yutrepia sales surge Yutrepia, Liquidia's lung drug, sold about $300 million in the first half of 2026, with over 5,000 patients started and a fourth straight profitable quarter. This rapid sales growth is the main reason the stock had more than doubled this year.
It shows the core business is growing fast, which is the main force pushing LQDA up.
Patent loss threatens key use A Delaware court ruled Yutrepia infringes a United Therapeutics patent covering its use for PH-ILD, a lung condition. If the ruling stands, Yutrepia could be restricted from that market, cutting future sales and profits.
This is the biggest new negative force, directly threatening a major part of Yutrepia's market.
Downgrades slash price targets Wells Fargo downgraded Liquidia to Equal Weight and cut its price target to $30 from $108, with BTIG and Raymond James also downgrading. These cuts reflect lost confidence in future growth and weigh on the stock.
It shows how the patent ruling changed analyst views, adding selling pressure on LQDA.
Fast Track for new use The FDA gave Fast Track status to Yutrepia for Raynaud's phenomenon linked to scleroderma, a new potential market. This speeds development and could add future sales, though it is still early and small compared to the patent risk.
It is a new positive regulatory step that could expand Yutrepia's label, offering a counterweight to the patent setback.

Latest5 Aug – 2 Oct 2026

▲2▼2

Liquidia's Yutrepia Boom Meets Patent Setback

Yutrepia sales surge Yutrepia, Liquidia's lung drug, sold about $300 million in the first half of 2026, with over 5,000 patients started and a fourth straight profitable quarter. This rapid sales growth is the main reason the stock had more than doubled this year.
It shows the core business is growing fast, which is the main force pushing LQDA up.
Patent loss threatens key use A Delaware court ruled Yutrepia infringes a United Therapeutics patent covering its use for PH-ILD, a lung condition. If the ruling stands, Yutrepia could be restricted from that market, cutting future sales and profits.
This is the biggest new negative force, directly threatening a major part of Yutrepia's market.
Downgrades slash price targets Wells Fargo downgraded Liquidia to Equal Weight and cut its price target to $30 from $108, with BTIG and Raymond James also downgrading. These cuts reflect lost confidence in future growth and weigh on the stock.
It shows how the patent ruling changed analyst views, adding selling pressure on LQDA.
Fast Track for new use The FDA gave Fast Track status to Yutrepia for Raynaud's phenomenon linked to scleroderma, a new potential market. This speeds development and could add future sales, though it is still early and small compared to the patent risk.
It is a new positive regulatory step that could expand Yutrepia's label, offering a counterweight to the patent setback.

July 202629 Jun – 22 Jul 2026

▲4

Yutrepia Sales Soar, Patent Ruling Favors Liquidia

Yutrepia launch drives rapid revenue growth and profitability Liquidia scaled annualized revenue from near zero to about $520 million in three quarters, with Q1 2026 sales of $130 million and a third straight profitable quarter. This shows strong demand and execution, pushing the stock up.
This is the core fundamental driver of LQDA's price surge.
Judge criticizes United Therapeutics in patent dispute A judge criticized United Therapeutics for altering an interrogatory response, calling it deceptive. This legal development reduces the risk of an adverse ruling that could remove Yutrepia from the market, boosting investor confidence.
This is a new legal development that directly affects the key risk overhang on the stock.
Yutrepia adoption metrics show strong market penetration Over 4,500 prescriptions, 3,750 patients, and nearly 1,000 prescribing physicians indicate robust adoption. 75% of new starts are treatment-naive, meaning the market is expanding, not just stealing share. This supports future growth expectations.
These metrics demonstrate the strength of the launch and its potential for continued growth.
Analyst and investor optimism, with price target increases Laughing Water Capital called the launch 'fantastic' and believes the worst-case patent outcome is off the table. The Zacks consensus EPS estimate for 2026 rose to $3.02 from $1.50, and the stock has surged over 130% year to date, reflecting growing confidence.
This shows third-party validation and improving earnings expectations, which drive stock price.

29 Jun – 22 Jul 2026

▲4

Yutrepia Sales Soar, Patent Ruling Favors Liquidia

Yutrepia launch drives rapid revenue growth and profitability Liquidia scaled annualized revenue from near zero to about $520 million in three quarters, with Q1 2026 sales of $130 million and a third straight profitable quarter. This shows strong demand and execution, pushing the stock up.
This is the core fundamental driver of LQDA's price surge.
Judge criticizes United Therapeutics in patent dispute A judge criticized United Therapeutics for altering an interrogatory response, calling it deceptive. This legal development reduces the risk of an adverse ruling that could remove Yutrepia from the market, boosting investor confidence.
This is a new legal development that directly affects the key risk overhang on the stock.
Yutrepia adoption metrics show strong market penetration Over 4,500 prescriptions, 3,750 patients, and nearly 1,000 prescribing physicians indicate robust adoption. 75% of new starts are treatment-naive, meaning the market is expanding, not just stealing share. This supports future growth expectations.
These metrics demonstrate the strength of the launch and its potential for continued growth.
Analyst and investor optimism, with price target increases Laughing Water Capital called the launch 'fantastic' and believes the worst-case patent outcome is off the table. The Zacks consensus EPS estimate for 2026 rose to $3.02 from $1.50, and the stock has surged over 130% year to date, reflecting growing confidence.
This shows third-party validation and improving earnings expectations, which drive stock price.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.